Clinic Roundup
• Atlab Pharma SAS, of Nantes, France, presented data at the European Cancer Congress in Amsterdam, from a Phase I trial with expansion cohorts involving 41 patients treated with fractionated doses of ATL101 for prostate cancer, reporting significant antitumor activity with a trend in dose-dependent effect on overall survival associated to a good tolerance and manageable myelotoxicity.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.